(MedPage Today) — The FDA approved a new starting dosage regimen for the subcutaneous formulation of lecanemab (Leqembi Iqlik) to treat adults with Alzheimer's disease, the agency said Monday. Lecanemab is an anti-amyloid monoclonal antibody…
Source: MedPage Today — Headlines
